Foenumoside B may protect irradiated lung tissue by activating AMPK-linked and antioxidant signaling.
Evidence
This preclinical study used a 20 Gy murine total lung irradiation model plus alveolar epithelial cell experiments, pharmacologic blockade, PINK1 silencing, docking, Co-IP, and ChIP assays.
Caveat
The evidence is preclinical and mechanism-heavy, with oral 10 mg/kg/day dosing in mice and cellular perturbation assays rather than human radiotherapy outcomes.
Simplified
(RILI) is a dose-limiting toxicity of thoracic radiotherapy driven by mitochondrial damage-mediated oxidative stress, persistent DNA damage, and senescence, which together destabilize the alveolar-interstitial niche and promote fibrosis. Here, we identify Foenumoside B (FSB), a natural saponin from Lysimachia foenum-graecum, as a dual-action modulator that preserves mitochondrial quality and restores systemic redox homeostasis to attenuate RILI. In a murine total lung irradiation model (20 Gy), oral FSB (10 mg/kg/day) mitigated inflammation and fibrotic remodeling, improved pulmonary mechanics and arterial blood gases, and exhibited no overt hepatorenal toxicity. Mechanistically, FSB activated PINK1/Parkin-dependent in alveolar epithelial cells. Pharmacologic autophagy blockade (3-MA) or PINK1 silencing abrogated these benefits, increasing mtROS, γH2AX foci, comet tail moments, and p16/p21 expression, and reducing cell viability, thereby confirming mitophagy as indispensable for FSB's cytoprotection. Molecular docking analysis demonstrates that FSB binds to the catalytic α1 and α2 subunits of AMPK, thereby significantly increasing the p-AMPK/AMPK ratio. Upon pharmacologic inhibition of AMPK, the FSB-mediated improvements in mitophagy, mitochondrial function, redox homeostasis, and tissue protection are markedly attenuated, indicating that FSB's biological effects rely on AMPK activation. FSB also restored Nrf2/HO-1 signaling and antioxidant capacity. Co-IP/ChIP showed AMPK directly associates with Nrf2, enhances its phosphorylation and ARE binding at the HO-1 promoter, and weakens Keap1-mediated degradation. Overall, FSB suppresses reactive oxygen species at their mitochondrial source and, through AMPK-driven mitophagy and Nrf2 activation, enhances endogenous antioxidant defenses, providing a translatable strategy to preserve alveolar architecture during radiotherapy.
Key numbers
Less body weight loss in FSB-treated TLI mice
Body Weight Loss Reduction
Compared to the control group in a murine model of
Significantly lower mRNA levels of Ccl2, IL-6, IL-1β, TNF-α in FSB treatment group
Inflammatory Cytokine Reduction
Measured in lung tissues of FSB-treated mice vs. TLI group
Full Text
We can’t show the full text here under this license.
